Michael P. Johnson - Concepedia

Author

Michael P. Johnson

Also Known As

M Johnson, M P Johnson, M. P. JOHNSON, M. P. Johnson, M.P Johnson, M.P. Johnson, Michael Johnson, Michael P Johnson, Michael P. Johnson

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Purdue University West Lafayette Eli Lilly (United Kingdom)

About

Michael P. Johnson is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	29	1.8K
2	Social Sciences	13	13	980
3	Natural Sciences	5	5	217
4	Health Sciences	1	1	72
5	Allergy	1	1	25

Michael P. Johnson

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Effects of enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices Michael P. Johnson, Andrew J. Hoffman, David E. Nichols European Journal of Pharmacology Psychoactive DrugPsychiatryNeurophysiologyNeuroanatomyMedicine	1986	307
Six-Hour Window of Opportunity for Calpain Inhibition in Focal Cerebral Ischemia in Rats Carrie G. Markgraf, Nelson L. Velayo, Michael P. Johnson, Stroke	1998	245
Identification of a GABAB Receptor Subunit, gb2, Required for Functional GABAB Receptor Activity Gordon Ng, Janet Clark, Nathalie Coulombe, Journal of Biological Chemistry Molecular BiologySocial SciencesMonomeric ReceptorsGabab Receptor SubunitCell Signaling	1999	212
Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of <i>N</i>-(4-(2-Methoxyphenoxy)phenyl)-<i>N</i>-(2,2,2− trifluoroethylsulfonyl)pyrid-3-ylmethylamine Michael P. Johnson, Melvyn Baez, G. Erik Jagdmann, Journal of Medicinal Chemistry Allosteric PotentiatorsMolecular PharmacologyBiochemistryMetabotropic Glutamate 2Medicine	2003	181
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) Michael P. Johnson, David A. Barda, Thomas C. Britton, Psychopharmacology Psychoactive DrugPsychiatryBehavioral NeuroscienceMetabotropic Glutamate 2Psychology	2005	154
Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Michael P. Johnson, Richard J. Loncharich, M Baez, Molecular Pharmacology	1994	107
[3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetaimne and p-chloroamphetamine analogues Michael P. Johnson, Paul F. Conarty, David E. Nichols European Journal of Pharmacology Medicinal ChemistryPsychoactive DrugPharmacological StudyMedicineNatural Sciences	1991	100
Peripheral and central nervous system distribution of the CGRP neutralizing antibody [<sup>125</sup>I] galcanezumab in male rats Kirk W. Johnson, Stéphanie Morin, Victor J. Wroblewski, Cephalalgia	2019	97
Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain Niklas Schuelert, C. Zhang, Adrian J. Mogg, Osteoarthritis and Cartilage Cannabis UseRheumatologyFunctional SelectivityPain MedicineMedicine	2010	76
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis Niklas Schuelert, Michael P. Johnson, J.L. Oskins, Pain Joint NociceptionNeuropathic PainMolecular PainMedicinal ChemistryOsteoarthritis	2010	72

Page 1